MINUTES
CIBMTR WORKING COMMITTEE FOR DONOR AND RECIPIENT HEALTH SERVICES WORKING COMMITTEE
Honolulu, HI
Friday, February 14, 2025, 1:00 – 3:00 PM HST

Co-Chair:	**Leslie Lehmann, MD; Dana Farber Cancer Institute, Boston, MA; Telephone: 617-632-4882; Email: leslie_lehmann@dfci.harvard.edu**
Co-Chair:	**Hemalatha Rangarajan, MD; Nationwide Children's Hospital, Columbus, OH; Telephone: 740-953-0602; E-mail: hemalatha.rangarajan@nationwidechildrens.org**
Co-Chair:	**Fotios Michelis, MD, PhD; Princess Margaret Cancer Center, Toronto, ON, Canada; E-mail: fotios.michelis@uhn.ca**
Co-Chair:	**Minoo Battiwalla, MD, MS; Sarah Cannon BMT Program, Nashville, TN; Telephone: 615-342-7644; E-mail: minoo.battiwalla@hcahealthcare.com**
Page Scholar:	**Megan Herr, PhD; Roswell Park, Buffalo, NY; Telephone: (716) 845-3557; Email: megan.herr@roswellpark.org**
Scientific Director:	**Heather Stefanski, MD, PhD; CIBMTR® (Center for International Blood and Marrow Transplant Research), Minneapolis, MN; Telephone: 763-406-8465; E-mail: hstefans@nmdp.org**
Statistical Director:	**Ruta Brazauskas, PhD; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-456-8687; E-mail: ruta@mcw.edu**
Statistical Director:	**Brent Logan, PhD; CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI; Telephone: 414-955-8849; E-mail: blogan@mcw.edu**
Statistician:	**Gabrielle Schmidt, MPH; CIBMTR® (Center for International Blood and Marrow Transplant Research), Minneapolis, MN; Telephone: 763-406-3841; E-mail: gschmidt@nmdp.org**

---

1. **Introduction**
   a. Minutes from February 2024 (Attachment 1)

2. **Accrual summary** (Attachment 2)

3. **Presentations, Publications or Submitted papers**
   a. **HS16-01a** Khera N, Ailawadhi S, Brazauskas R, Patel J, Jacobs B, Ustun C, Ballen K, Abid MB, Diaz Perez MA, Al-Homsi AS, Hashem H, Hong S, Munker R, Schears RM, Lazarus HM, Ciurea S, Badawy SM, Savani BN, Wirk B, LeMaistre CF, Bhatt NS, Beitinjaneh A, Aljurf M, Sharma A, Cerny J, Knight JM, Kelkar AH, Yared JA, Kindwall-Keller T, Winestone LE, Steinberg A, Arnold SD, Seo S, Preussler JM, Hossain NM, Fingrut WB, Agrawal V, Hashmi S, Lehmann LE, Wood WA, Rangarajan HG, Saber W, Hahn T. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities. ***Blood Advances. 2024 Jul 9; 8(13):3497-3506. doi:10.1182/bloodadvances.2023012469. Epub 2024 Apr 25. PMC11260842.***
   b. **HS16-01b** Hahn T, Herr MM, Brazauskas R, Patel J, Ailawadhi S, Saber W, Khera N. Use of hematopoietic cell transplant for hematologic cancers by race, ethnicity, and age. ***JAMA***

Network Open. 2024 Sep 3; doi:10.1001/jamanetworkopen.2024.33145. Epub 2024 Sep 18. PMC11411389.

c. **HS16-03** Ballen K, Wang T, He N, Knight JM, Hong S, Frangoul H, Verdonck LF, Steinberg A, Diaz MA, LeMaistre CF, Badaway SM, Pu JJ, Hashem H, Savani B, Sharma A, Lazarus HM, Abid MB, Tay J, Rangarajan HG, Kindwall-Keller T, Freytes CO, Beitinjaneh A, Winestone LE, Gergis U, Farhadfar N, Bhatt NS, Schears R, Gómez-Almaguer D, Aljurf M, Agrawal V, Kuwatsuka Y, Seo S, Marks DI, Lehmann L, Wood WA, Hashmi S, Saber W. Impact of Race/Ethnicity on Outcomes after Umbilical Cord Blood Transplantation. ***Transplantation and Cellular Therapy. 2024 Oct 30; 30(10):1027.el – 1027.e14. doi:10.1016/j.jtct.2024.07.009. Epub 2024 Jul 19.***

d. **HS18-01** Efficacy of Intensified Myeloablative Regimens for Acute Leukemia – An International Collaborative study. (Y Arai/ Y Atsuta/ S Yano). ***Submitted.***

4. **Studies in progress** (Attachment 3)
   a. **DS20-01** Acute toxicities of bone marrow donation in donors with sickle cell trait (N Farhadfar/ J Wingard). **Manuscript Preparation.**
   b. **HS18-03** Racial/ethnic disparities in receipt of hematopoietic cell transplantation and subsequent resource utilization in children with acute leukemia. (L Winestone/ R Aplenc/ K Getz). **Datafile preparation.**
   c. **HS19-01** Factors Associated with Clinical Trial Participation among HCT Patients: A CIBMTR Analysis (T F. Gray/ A El-Jawahri). **Analysis.**
   d. **HS19-03** Haploidentical stem cell transplantation for malignant and non-malignant hematological diseases in patients without sibling donor: a multicenter prospective longitudinal study of the Brazilian bone marrow transplantation study group (N Hamerschlak/ M Kerbauy/ A Riberio). **Submitted.**
   e. **HS20-01** Resource Intensity of End-of-Life Care in Children After Hematopoietic Stem Cell Transplant for Acute Leukemia: Rates and Disparities (E E Johnston/ C W. Elgarten/ L Winestone/ R Aplenc/ K Getz/ V Huang/ Y Li). **Datafile preparation.**
   f. **HS22-01** Health care utilization and costs of haploidentical allogeneic stem cell transplants in a contemporary cohort of pediatric patients with acute leukemia and myelodysplastic syndrome. (H Rangarajan/ P Satwani). **Protocol Received.**
   g. **HS23-01** Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation in the United States. (B Hamilton/ S Hong). **Protocol Received.**
   h. **DRS24-01** Outcomes for medicaid beneficiaries following allogeneic hematopoietic cell transplantation: Exploring the impact of variable medicaid eligibility criteria. (P DeMartino/ N Majail). **Protocol Received.**

5. **Future/proposed studies**
   a. **PROP 2410-133** Impact of Race and Ethnicity on Incidence of Primary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplant Recipients (H Rangarajan/ M Kharfan Dabaja) (Attachment 4)

      Dr. Karfan Dabaja presented.

      - *Key Points:*
        - *Significant advances in transplantation over the past 4 decades.*
        - *Graft failure remains a challenge, reported in up to 20% of cases.*
        - *Objectives include assessing the impact of race and ethnicity on graft failure and comparing outcomes stratified by race and ethnicity.*

- *Discussion:*
    - *Concerns about confounding factors such as donor HLA match and disease heterogeneity.*
    - *Suggestions to separate malignant and non-malignant diseases and consider the use of second transplants.*

b. **PROP 2409-02; 2410-57** Do housing distance requirements imposed by transplant centers on hematopoietic cell transplantation patients affect non-relapse mortality and other clinical outcomes (C Su/ R Salit) (Attachment 5)

Dr. Salit presented.

- *Key Points:*
    - *Significant financial hardship caused by housing distance requirements.*
    - *Primary outcome: Non-relapsed mortality in the first 100 days.*
    - *Secondary outcomes: Unplanned admissions, hospitalization days, acute GVHD, infections, organ impairment, survival, and disease relapse.*
- *Discussion:*
    - *Challenges in obtaining data from multiple centers.*
    - *Variability in distance requirements and compliance.*

c. **PROP 2410-03** Racial and Ethnic Discrepancies in Clinical Outcomes of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma in Non-Hispanic Black and Hispanic Populations as Compared to Caucasian Patients (P Hagen) (Attachment 6)

Dr. Carrigan presented.

- *Key Points:*
    - *Disparities in access to optimal care for multiple myeloma patients.*
    - *Hypothesis: Outcomes are equal among racial and ethnic groups after transplant.*
    - *Primary outcome: Progression-free survival.*
    - *Secondary outcome: Overall survival.*
- *Discussion:*
    - *Importance of evaluating outcomes in a cohort that received optimal care.*

d. **PROP 2410-23; 2410-179** The Effect of Social Determinants of Health on Outcomes in Pediatric and Adolescent/Young Adult (AYA) Patients Undergoing Haploidentical Stem Cell Transplantation for Malignant and Non-Malignant Disease (Y Berry/ S Farhan/ L Davis/ P Satwani) (Attachment 7)

Dr. Davis presented.

- *Key Points:*
    - *Impact of social determinants of health on transplant outcomes.*
    - *Inclusion criteria: Patients aged 0-39 undergoing haploidentical transplant from 2010 to 2022.*
    - *Primary outcome: Overall survival.*

        - *Secondary outcomes: Treatment-related mortality, leukemia-free survival, GVHD, and post-transplant complications.*
    - *Discussion:*
        - *Concerns about missing zip code data and race/ethnicity information.*
        - *Suggestions to focus on patients with available zip codes and separate malignant and non-malignant diseases.*

e. **PROP 2410-80** Defibrotide prophylaxis for hepatic sinusoidal obstructive syndrome in pediatric hematopoietic cellular therapy recipients: real-world outcomes and health care utilization implications (M Schoettler/ K Williams) (Attachment 8)

Dr. Schoettler presented.

- *Key Points:*
    - *Impact of defibrotide prophylaxis on severe SOS and healthcare utilization.*
    - *Primary endpoint: Severe SOS defined as multi-organ dysfunction.*
    - *Secondary endpoints: Healthcare utilization, days in hospital, ICU days, procedures, and cost.*
- *Discussion:*
    - *Importance of combining CIBMTR and PHIS data for comprehensive analysis.*
    - *Challenges in determining defibrotide prophylaxis from PHIS data alone.*

Proposed studies; not accepted for consideration at this time

f. **PROP 2409-11** The impact of race and ethnicity on outcomes of patients treated with B-cell maturation antigen chimeric antigen receptor therapy for relapsed/refractory multiple myeloma (K J Feliciano-Salva/ D K Hansen). ***Dropped due to overlap with current study/publication.***
g. **PROP 2410-09** Racial disparity in outcomes after myeloablative conditioning for hematological malignancies in patients above the age of 45 years undergoing hematopoietic stem cell transplantation (D Lad). ***Dropped due to overlap with current study/publication.***
h. **PROP 2410-41** Disparities in allograft outcomes for patients with acute myeloid leukemia in the era of post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis (W Fingrut/ K Ballen). ***Dropped due to overlap with current study/publication.***
i. **PROP 2410-107** Social and economic determinants of health in multiple myeloma patients treated with commercial CAR T-cell therapies (M Krem/ N Ahmed). ***Dropped due to small sample size.***
j. **PROP 2410-111** Outcomes of BCMA directed Chimeric Antigen Receptor (BCMA.CAR T-cells) in Multiple Myeloma Patients from Rural America: A CIBMTR analysis (I Muhsen/ S Ganguly). ***Dropped due to supplemental data needed.***
k. **PROP 2410-138** Long term complications and outcomes among the patients treated with CAR-T cell therapy based on racial and demographic differences (E Umyarova/ N Epperla). ***Dropped due to low scientific impact.***
l. **PROP 2410-147** Impact of Race and Ethnicity on Outcomes for AYA patients with B-ALL Receiving CD19 CAR T-cell Therapy (H Lust/ E Burns). ***Dropped due to low scientific impact.***
m. **PROP 2410-157** Racial, ethnicity and socioeconomic disparity in outcomes of adolescent and young adults (15-39yo) undergoing allogeneic hematopoietic cell transplantation (M Daunov/ L Metheny). ***Dropped due to overlap with current study/publication.***

n. **PROP 2410-174** The Impact of Social Determinant of Health and Area of Residence on Outcomes of CD19 directed Chimeric Antigen Receptor (CD19.CAR T-cells) in Indolent Non-Hodgkin Lymphoma Patients: A CIBMTR analysis (I Muhsen/ E Burns). ***Dropped due small sample size.***
o. **PROP 2410-201** Impact of Pre-existing Mental Health Disorders on CAR T-cell Therapy Outcomes in Patients with Large B-cell Lymphoma (S Gouni/ S Ahmed). ***Dropped due to supplemental data needed.***
p. **PROP 2410-224** Social and economic determinants of health and long-term outcomes in acute lymphoblastic leukemia patients treated with commercial CAR T-cell therapies (M Krem/ N Ahmed). ***Dropped due to small sample size.***

6. Other business